PRASCEND® (pergolide mesylate) Case Studies1,2

This page is dedicated exclusively to helping veterinarians like you share information that will lead to even greater success in diagnosing and treating equine PPID patients. We will regularly feature new case studies, so you can find out about management and treatment approaches that have worked well for other veterinarians from around the country.

In addition, we invite you to join PPID Veterinary Partners. You'll receive free postcard mailers and in-clinic PPID educational materials to use with your clients. You'll also get the latest scientific information from leading endocrinologists related to diagnosing and managing PPID.

Important safety information

PRASCEND is for use in horses only. Treatment with PRASCEND has been observed to cause inappetance, with most cases being transient. Weight loss, lethargy, and behavioral changes may be observed in some horses. If severe, a temporary reduction of dose may be necessary. PRASCEND has not been evaluated in breeding, pregnant, or lactating animals. As PRASCEND is a dopamine agonist, it may interfere with reproductive hormones involved in these groups of animals. The concurrent use of dopamine antagonists should be avoided since these agents may diminish the effectiveness of PRASCEND. PRASCEND should not be used in horses with hypersensitivity to pergolide mesylate or other ergot derivatives. Refer to the package insert for complete product information.

References:

  1. PRASCEND® (pergolide mesylate) [package insert]. St. Joseph, MO: Boehringer Ingelheim Vetmedica, Inc.; 2011.
  2. PRASCEND® (pergolide mesylate) [Freedom of Information Summary]. St Joseph, MO: Boehringer Ingelheim Vetmedica, Inc.; 2011.